JPRN-jRCT2031210528进行中（未招募）3 期
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study
Tanaka Yoshiyuki0 个研究点目标入组 32 人开始时间: 2021年12月26日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Is currently receiving DOR/ISL adult FDC tablet in a Merck-sponsored clinical study and has completed the last treatment visit.
- •- Is considered by the investigator to have derived clinical benefit from receiving DOR/ISL and for whom further treatment with DOR/ISL is considered clinically appropriate.
- •- Is male or female and >=35 kg at the time of signing the informed consent/assent.
- •- Female is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP); or is a non-pregnant WOCBP who agrees to the following during the intervention period and for at least 6 weeks after the last dose of study intervention: Not be sexually active, or if sexually active, to use an acceptable method of contraception
排除标准
- •Is taking or is anticipated to require any prohibited therapies.
研究者
相似试验
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesEUCTR2020-001191-14-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2020-001191-14-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesEUCTR2020-001191-14-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
1 期
DOR/ISL Open-label Rollover TrialCTIS2024-512215-53-00Merck Sharp & Dohme LLC820
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-002215-22-NLBioverativ Therapeutics Inc.90